BioCryst Pharmaceuticals Statistics

Total Valuation

FRA:BO1 has a market cap or net worth of EUR 1.37 billion. The enterprise value is 1.78 billion.

Market Cap	1.37B
Enterprise Value	1.78B

Important Dates

The next estimated earnings date is Tuesday, February 24, 2026.

Earnings Date	Feb 24, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	210.54M
Shares Outstanding	n/a
Shares Change (YoY)	+1.84%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	1.03%
Owned by Institutions (%)	87.38%
Float	180.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	13.50
PS Ratio	2.69
PB Ratio	-4.16
P/TBV Ratio	n/a
P/FCF Ratio	33.68
P/OCF Ratio	32.11
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 25.04, with an EV/FCF ratio of 43.59.

EV / Earnings	-237.61
EV / Sales	3.45
EV / EBITDA	25.04
EV / EBIT	26.74
EV / FCF	43.59

Financial Position

The company has a current ratio of 1.87

Current Ratio	1.87
Quick Ratio	1.60
Debt / Equity	n/a
Debt / EBITDA	8.27
Debt / FCF	14.27
Interest Coverage	0.87

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	10.31%
Return on Invested Capital (ROIC)	14.46%
Return on Capital Employed (ROCE)	30.20%
Revenue Per Employee	881,419
Profits Per Employee	-12,901
Employee Count	580
Asset Turnover	1.28
Inventory Turnover	29.60

Taxes

In the past 12 months, FRA:BO1 has paid 1.84 million in taxes.

Income Tax	1.84M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.30% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-5.30%
50-Day Moving Average	6.05
200-Day Moving Average	7.21
Relative Strength Index (RSI)	67.67
Average Volume (20 Days)	43

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.47

Income Statement

In the last 12 months, FRA:BO1 had revenue of EUR 511.22 million and -7.48 million in losses. Loss per share was -0.04.

Revenue	511.22M
Gross Profit	349.83M
Operating Income	65.93M
Pretax Income	-5.64M
Net Income	-7.48M
EBITDA	68.55M
EBIT	65.93M
Loss Per Share	-0.04

Full Income Statement

Balance Sheet

The company has 181.43 million in cash and 582.21 million in debt, giving a net cash position of -400.78 million.

Cash & Cash Equivalents	181.43M
Total Debt	582.21M
Net Cash	-400.78M
Net Cash Per Share	n/a
Equity (Book Value)	-330.60M
Book Value Per Share	-1.57
Working Capital	141.01M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 42.78 million and capital expenditures -2.00 million, giving a free cash flow of 40.79 million.

Operating Cash Flow	42.78M
Capital Expenditures	-2.00M
Free Cash Flow	40.79M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 68.43%, with operating and profit margins of 12.90% and -1.46%.

Gross Margin	68.43%
Operating Margin	12.90%
Pretax Margin	-1.10%
Profit Margin	-1.46%
EBITDA Margin	13.41%
EBIT Margin	12.90%
FCF Margin	7.98%

Dividends & Yields

FRA:BO1 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.84%
Shareholder Yield	-1.84%
Earnings Yield	-0.54%
FCF Yield	2.97%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:BO1 has an Altman Z-Score of -1.89 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.89
Piotroski F-Score	6